The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells
Open Access
- 8 April 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 25 (7), 1182-1188
- https://doi.org/10.1038/leu.2011.60
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Targeting the bone microenvironment in multiple myelomaJournal of Bone and Mineral Metabolism, 2010
- Multiple myelomaThe Lancet, 2009
- Bone marrow microenvironment and the identification of new targets for myeloma therapyLeukemia, 2008
- BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myelomaLeukemia, 2006
- Bone Destruction in Multiple MyelomaAnnals of the New York Academy of Sciences, 2006
- The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signatureBlood, 2005
- Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survivalBlood, 2005
- Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansionBlood, 2004
- BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasoneBlood, 2004
- Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survivalBlood, 2004